George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.32
Bid: 9.32
Ask: 9.48
Change: -0.09 (-0.95%)
Spread: 0.16 (1.717%)
Open: 9.50
High: 9.50
Low: 9.32
Prev. Close: 9.49
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Dealing

15 Apr 2020 15:10

RNS Number : 7796J
Oxford BioDynamics PLC
15 April 2020
 

15 April 2020

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing

 

Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Vulpes Testudo Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 10,000 Ordinary Shares of 1 pence each ("shares") at a price of 50.5p per share.

 

Following this transaction, Vulpes Testudo Fund is interested in 303,002 Ordinary Shares, representing 0.33% of the Company's current issued share capital. Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested in 12,113,672 shares, representing approximately 13.09% of the Company's current issued share capital. 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Stephen Diggle

2

Reason for the notification

a)

Position/status 

Director/PDMR

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc 

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each

 

ISIN: GB00BD5H8572

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

0.505

10,000

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

Price

Volume

0.505

10,000

 

 

e)

Dates of the transaction

14 April 2020 

f)

Place of the transaction

Outside a trading venue

 

 

For further details please contact:

 

Oxford BioDynamics Plc

Jon Burrows, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

Shore Capital

Nominated Adviser and Broker

Stephane Auton

Edward Mansfield

John More

 

+44 (0)20 7408 4090

FTI Consulting

Financial Public Relations Adviser

Natalie Garland-Collins

 

+44 (0)20 3727 1000

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

 

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHIAMITMTMBBRM
Date   Source Headline
27th Mar 20242:18 pmRNSResult of AGM
14th Mar 20247:00 amRNSResults of Fundraising
13th Mar 20244:45 pmRNSPrimaryBid Offer
13th Mar 20244:40 pmRNSProposed Fundraising
22nd Feb 20242:30 pmRNSAnnual Report & Accounts
17th Jan 20247:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20237:20 amRNSNotice of Results
13th Nov 202310:22 amRNSDirector/PDMR Shareholding
8th Nov 20237:00 amRNSOBD strengths commercial leadership
7th Nov 202312:30 pmRNSHolding(s) in Company
6th Nov 20235:04 pmRNSHolding(s) in Company
3rd Nov 20239:29 amRNSDirector/PDMR Shareholding
23rd Oct 202311:09 amRNSPDMR Dealing / Grant of Share Options
20th Oct 20239:45 amRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSBupa UK to cover EpiSwitch® CiRT for customers
6th Oct 20235:44 pmRNSDirector/PDMR Shareholding
3rd Oct 20234:37 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSOBD receives reimbursement code for PSE test
26th Sep 20237:00 amRNSOBD launches 94% accurate PSE test in US and UK
7th Sep 202310:18 amRNSHolding(s) in Company
1st Sep 202312:34 pmRNSAmendment: Director/PDMR Shareholding
31st Aug 20234:02 pmRNSHolding(s) in Company
25th Aug 20239:00 amRNSHolding(s) in Company
22nd Aug 20233:58 pmRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
18th Aug 202311:44 amRNSResult of General Meeting
8th Aug 20234:00 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSResults of PrimaryBid Offer
2nd Aug 20237:00 amRNSResult of Placing and Subscription
1st Aug 20234:55 pmRNSPrimaryBid Offer
1st Aug 20234:54 pmRNSProposed Fundraising
30th May 20237:00 amRNSHalf-year Report
16th May 20237:00 amRNSNotice of Interim Results and Investor Webinar
15th May 20237:00 amRNSCiRT expanded validation for ICI immunotherapies
2nd May 20237:00 amRNSUS PACT Award for prognosis test for IOrelated HPD
18th Apr 20237:00 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSBusiness update for PSE and CiRT tests
30th Mar 20231:04 pmRNSResult of AGM
23rd Mar 20233:19 pmRNSHolding(s) in Company
22nd Mar 20232:22 pmRNSHolding(s) in Company
15th Mar 202311:43 amRNSAIM Rule 17 Schedule 2(g) Update
3rd Mar 20234:33 pmRNSPublication of FY22 Annual Report
23rd Feb 202310:36 amRNSPDMR Dealing
6th Feb 20237:00 amRNSOBD Prostate Screening EpiSwitch Blood Test Update
27th Jan 20232:36 pmRNSDirector/PDMR Shareholding
24th Jan 20237:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20227:00 amRNSNotice of FY22 Results and Investor Webinar
19th Dec 20227:00 amRNSOBD in San Francisco for JPM Healthcare conf 2023
16th Dec 20227:00 amRNSInitial assessment of EpiSwitch assay in ALS trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.